Oral etoposide plus anlotinib and subcutaneous envafolimab as a platinum‑free, non‑intravenous first‑line regimen for elderly extensive‑stage small cell lung cancer: a phase II trial with biomarker discovery
International Open Medical Journal (IOMJ) · 09.11.2026 · 2 · 227-243
DOI: 10.65364/iomj.2026.12 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Open Medical Journal (IOMJ), online erschienen am 09.11.2026. Verfasst von Man Zhang und 12 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To evaluate the efficacy and safety of a non-IV, platinum-free regimen (oral etoposide + anlotinib + envafolimab) in treatment-naïve elderly patients with extensive-stage small cell lung cancer (ES-SCLC).
Methods
Twenty-five elderly patients with ES-SCLC were enrolled. The regimen included etoposide 100 mg PO daily (days 1-7), anlotinib 12 mg PO daily (days 1-14), and envafolimab 300 mg SC per dose, repeated every 21 days for 4–6 cycles until progression or intolerance.
Results
Mean age was 73.7 ± 3.2 years. ORR was 68%, DCR 96%. Median PFS was 5.23 months (95% CI: 4.5–NA) and median OS 7.53 months (95% CI: 6.28–NA). Grade ≥3 AEs included neutropenia (16.0%), ALT/AST elevation (8.0%), immune-related pneumonitis (8.0%), and cardiac dysfunction (4.0%). No platinum-related severe toxicities occurred; 56.0% required no antiemetics. Responders showed upregulation of FAM230A and NAT16, downregulation of BMP4, and increased eosinophil infiltration. Non-responders featured naive/memory B-cell infiltration. Longer PFS correlated with high RET/WDR65 expression and cell cycle/immune activation pathways, while shorter PFS was associated with plasma cell infiltration and aggressive tumor features.
Conclusion
This oral, platinum-free, non-IV regimen demonstrated efficacy comparable to standard first-line therapy in elderly ES-SCLC, with significantly lower toxicity, better convenience, and superior tolerability, supporting its use as a preferred first-line option. The identified biomarkers may aid individualized efficacy prediction.
Zitieren
APA
Zhang, M., Sun, H., Xing, S., Li, Y., Zhao, G., Wang, H., Zuo, R., Li, S., Wang, B., Yan, Z., Xu, J., Pan, Z., & Jiang, Z. (2026). Oral etoposide plus anlotinib and subcutaneous envafolimab as a platinum‑free, non‑intravenous first‑line regimen for elderly extensive‑stage small cell lung cancer: a phase II trial with biomarker discovery. International Open Medical Journal (IOMJ), 2, 227-243. https://doi.org/10.65364/iomj.2026.12
Vancouver
Zhang M, Sun H, Xing S, Li Y, Zhao G, Wang H, et al. Oral etoposide plus anlotinib and subcutaneous envafolimab as a platinum‑free, non‑intravenous first‑line regimen for elderly extensive‑stage small cell lung cancer: a phase II trial with biomarker discovery. International Open Medical Journal (IOMJ). 2026;2:227-243. doi:10.65364/iomj.2026.12
BibTeX
@article{Zhang2026,
author = {Zhang, Man and Sun, Haiyan and Xing, Sijia and Li, Yanyang and Zhao, Gang and Wang, Huiya and Zuo, Ran and Li, Shuang and Wang, Bin and Yan, Zhuchen and Xu, Jie and Pan, Zhanyu and Jiang, Zhansheng},
title = {Oral etoposide plus anlotinib and subcutaneous envafolimab as a platinum‑free, non‑intravenous first‑line regimen for elderly extensive‑stage small cell lung cancer: a phase II trial with biomarker discovery},
journal = {International Open Medical Journal (IOMJ)},
year = {2026},
volume = {2},
pages = {227--243},
doi = {10.65364/iomj.2026.12}
}
EUVIMED